Daily News Podcast

Rivaroxaban beats aspirin for VTE


 

Both low-dose and full-dose rivaroxaban had superior benefit-risk profiles for extended VTE compared with aspirin. Also today, bone biopsy diagnostics for osteomyelitis vary widely, variation in bacterial drug susceptibility are tied to the risk of TB relapse, and CTA cuts MIs in patients with stable chest pain. Subscribe to the MDedge Daily News wherever you get your podcasts.
Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

When your patients are your neighbors
MDedge Family Medicine
Sleepio app tied to reducing insomnia, depression
MDedge Family Medicine
5 digital HIPAA myths
MDedge Family Medicine
Screen for cervical cancer based on age, risk
MDedge Family Medicine
Is it time for PCPs to take over chronic HCV?
MDedge Family Medicine
Rivaroxaban data abound at ESC 2018
MDedge Family Medicine
Children and teens are at risk for drug-drug interactions
MDedge Family Medicine
New MI definition for infarction vs injury
MDedge Family Medicine
Lorcaserin shows cardiovascular safety
MDedge Family Medicine
Lung function decline linked to cardiovascular risk
MDedge Family Medicine